MITF and melanoma: Detailed reports witnessing the reactivation of PKA-CREB-MITF axis in melanoma patients relapsing from vemurafenib,9 and the revelation of a MITF-dependent shift in metabolic preference from anaerobic glycolysis to oxidative phosphorylation in melanoma cells developing vemurafenib resistance17 underscore MITF's acquired drug resistance credentials.